The clinical significance of TET enzymes, including TET1, TET2, and TET3, was assessed by examining their genetic alterations in cBioPortal.31 We noted a higher frequency of TET alterations in metastatic castration-resistant prostate cancer (mCRPC) compared to primary prostate cancer (Supplementary information, Fig. S9d, e). This evidence concerns the gene TET3 and prostate carcinoma.